iRhythm Technologies, Inc.
NASDAQ•IRTC
CEO: Mr. Quentin S. Blackford
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2016-10-20
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Contact Information
Market Cap
$5.44B
P/E (TTM)
-105.5
33
Dividend Yield
--
52W High
$212.00
52W Low
$84.17
52W Range
Rank65Top 87.9%
2.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$192.88M+30.73%
4-Quarter Trend
EPS
-$0.16-89.19%
4-Quarter Trend
FCF
$20.05M+29.26%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Growth Strong 31% Net revenue for three months ended September 30, 2025, reached $192.9M, marking a 31% increase over the prior period.
Gross Profit Margin Expansion Nine months gross profit totaled $379.2M, showing a 30% increase, driven by volume growth and product mix shifts.
Operating Cash Flow Positive Cash provided by operating activities was $54.7M for nine months 2025, reversing prior period usage of $15.8M.
Net Loss Significantly Reduced Nine months net loss narrowed to $50.1M in 2025 from $112.0M in 2024, reflecting operational leverage.
Risk Factors
Macroeconomic Headwinds Persist Global uncertainty, inflation, and interest rate volatility could tighten hospital budgets, negatively impacting service prescription rates.
Reimbursement Rate Uncertainty CMS updates reimbursement rates annually; future reductions in CPT code rates could adversely affect financial results significantly.
Ongoing Patent Litigation Costs Intellectual property litigation expenses totaled $7.0M for nine months 2025, stemming from active lawsuits with competitors.
Supply Chain Single-Source Reliance Reliance on single-source vendors for critical Zio patch components risks delays and increased expenses if supply is disrupted.
Outlook
Liquidity Sufficient for 12 Months Current cash, securities, and receivables balances are deemed sufficient to meet liquidity requirements for the next 12 months.
BiolS Milestone Achieved First of two BiolS regulatory milestones achieved in June 2025, potentially leading to cancellation of $10.0M in Milestone Notes.
Continued R&D Investment Focus Expect research and development costs to increase in absolute dollars hiring personnel for new product enhancements and clinical evidence.
Evaluating New Accounting Standards Management is currently evaluating the impact of several recently issued accounting standards updates on future financial disclosures.
Peer Comparison
Revenue (TTM)
OSCR$11.29B
$4.97B
BRKR$3.44B
Gross Margin (Latest Quarter)
AXSM93.0%
GKOS78.4%
71.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NUVL | $7.62B | -19.8 | -39.5% | 0.0% |
| AXSM | $7.47B | -32.3 | -357.2% | 32.3% |
| BRKR | $6.85B | -345.7 | -1.0% | 31.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.5%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Research & Insights
Next earnings:Feb 19, 2026
EPS:$0.02
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $192.88M+30.7%|EPS: $-0.16-89.2%BeatForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 31, 2025|Revenue: $186.69M+26.1%|EPS: $-0.45-30.8%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 1, 2025|Revenue: $158.68M+20.3%|EPS: $-0.97-34.0%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 20, 2025|Revenue: $591.84M+20.1%|EPS: $-3.63+10.1%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 30, 2024|Revenue: $147.54M+18.4%|EPS: $-1.48+66.3%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 1, 2024|Revenue: $148.05M+19.3%|EPS: $-0.65+6.6%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 2, 2024|Revenue: $131.93M+18.4%|EPS: $-1.47+14.0%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 22, 2024|Revenue: $492.68M+19.9%|EPS: $-4.04-4.1%Miss